Keywords: cancer; cardiomyopathy; cardioprotection; chemotherapy; doxorubicin; heart failureACE, angiotensin-converting enzyme; ALL, acute lymphoblastic leukemia; ARB, angiotensin receptor blocker; DNA, deoxyribonucleic acid; FDA, U.S. Food and Drug Administration;